BLA 125509 · Elusys Therapeutics INC
Anthim
Obiltoxaximab · Injection · Anthrax Protective Antigen-directed Antibody
NovelOrphanLast checked: Nov 20, 2026Latest source record: Nov 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Mar 18, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
0 Phase 3, 0 recruiting
FAERS reports
2
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY and ANAPHYLAXIS Hypersensitivity and anaphylaxis have been reported during the intravenous infusion of ANTHIM. Due to the risk of hypersensitivity and anaphylaxis, ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Monitor individuals who receive ANTHIM closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of time after administration. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs [see Indications and Usage ( 1.2 ), Dosage and Administration ( 2.4 ) and Warnings and Precautions ( 5.1 )]. WARNING: HYPERSENSITIVITY and ANAPHYLAXIS See full prescribing information for complete boxed warning. Hypersensitivity reactions, including anaphylaxis, have been reported during ANTHIM infusion ( 5.1 ) ANTHIM should be...
What it is approved for
From the label in effect Sep 14, 2026.
ANTHIM ® is a monoclonal antibody directed against the protective antigen of Bacillus anthracis . It is indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ( 1.1 ) Limitations of Use ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. ( 1.2 , 5.1 ) The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. ( 1.2 , 14 ) There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. ( 1.2 , 8.4 ) ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. ( 1.2 ) ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis. ( 1.2 ) 1.1 Inhalational Anthrax ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. ANTHIM is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or not appropriate [see Indications and Usage ( 1.2 )] . 1.2 Limitations of Use ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis [see Warnings and Precautions ( 5.1 )] . The effectiveness of ANTHIM is based solely on efficacy studies in animal models of...
Mechanism: Obiltoxaximab is a monoclonal antibody that binds the PA of B. anthracis [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 18, 2016 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewSummary Review
1 products under this application
- ANTHIM · OBILTOXAXIMAB 600MG/6ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Obiltoxaximab" as an intervention, any sponsor and status, largest first.
- Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult VolunteersPivotal-lookingCompleted
Elusys TherapeuticsAcademic, hospital or other
NCT01929226 · 280 participants · Start Jul 9, 2013 · Primary completion Nov 29, 2013
Drug: ETI-204 · For: Inhalational Anthrax
Sites: Dallas, Texas
- Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult VolunteersPivotal-lookingCompleted
Elusys TherapeuticsAcademic, hospital or other
NCT01453907 · 108 participants · Start Oct 2011 · Primary completion Jun 2012
Drug: ETI-204, "Anthim"; placebo · For: Anthrax
Sites: Overland Park, Kansas
- An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. AnthracisStatus unknown
Elusys TherapeuticsAcademic, hospital or other
NCT03088111 · 100 participants (planned) · Start Dec 2023 · Primary completion Dec 2023
Drug: Obiltoxaximab · For: Infection, Bacterial; Anthrax
- Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult VolunteersCompleted
Elusys TherapeuticsAcademic, hospital or other
NCT01932242 · 70 participants · Start Jul 23, 2013 · Primary completion Apr 19, 2014
Drug: ETI-204 · For: Inhalational Anthrax
Sites: Overland Park, Kansas; Minneapolis, Minnesota
Elusys TherapeuticsAcademic, hospital or other
NCT00829582 · 45 participants (planned) · Start Feb 2009 · Primary completion Jul 2009
Drug: ETI-204, "Anthim" · For: Healthy Volunteers
Sites: Columbus, Ohio
Elusys TherapeuticsAcademic, hospital or other
NCT01952444 · 40 participants · Start Oct 29, 2013 · Primary completion Apr 9, 2014
Drug: ETI-204; Ciprofloxacin · For: Inhalational Anthrax
Sites: Overland Park, Kansas
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00138411 · 36 participants · Start Oct 2005
Drug: Ciprofloxacin 500 mg; ETI-204 (Anthim) · For: Bacillus Anthracis (Anthrax)
Sites: Columbus, Ohio
Elusys TherapeuticsAcademic, hospital or other
NCT01932437 · 36 participants · Start Jul 26, 2013 · Primary completion Jul 3, 2014
Drug: ETI-204 · For: Inhalational Anthrax
Sites: Dallas, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- congenital diaphragmatic hernia2
- maternal drugs affecting foetus2
- maternal exposure during pregnancy2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans.
Nagy CF, Leach TS, King A, et al. · Clin Pharmacol Drug Dev 2018 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
Nagy CF, Leach TS, Hoffman JH, et al. · Clin Ther 2016 · Multicenter Study, Randomized Controlled Trial
Sponsor: Elusys Therapeutics INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.